Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta is supported by early autoimmune-disease data that look clinically meaningful, with 83% of idiopathic inflammatory myopathy patients and 86% of systemic sclerosis patients showing responses at the 4B cell dose, alongside no CRS, ICANS, IEC-HS, or GvHD across all dose levels. Its off-the-shelf CAR-NK platform is attractive because it may deliver CAR-T-like efficacy with simpler logistics, outpatient feasibility, and less persistent immune toxicity, while also enabling dose optimization up to 6B cells and potentially stronger exposure. Fundamentally, the thesis is strengthened by a sizable addressable market, an early reset of B cells toward naïve and immature populations, and modeled peak sales potential around $1.9B to $2.0B in key indications despite the program still being clinical-stage.

Nkarta is challenged by the fact that all of its clinical programs remain in Phase I, leaving efficacy, durability, and safety largely unproven while there is no guarantee it can generate additional successful candidates from its platform or Crispr collaboration. The competitive backdrop is also crowded in IIM and SSc, yet no NK cell therapies have been approved by the FDA or EMA, increasing both development and regulatory risk for a company still trying to validate its lead program. Financially, 2Q26 showed a GAAP net loss of $40M, or $(0.54)/share, driven by $43M in OpEx, including $29M in R&D and $14M in SG&A, and despite ~$243M cash the company is expected to need additional funding to advance toward commercialization.